UFC GYM® Unveils Powerful Franchise Opportunity with UFC GYM Jiu-Jitsu

New Studio Model Empowers Entrepreneurs to Capitalize on Booming Jiu-Jitsu Market with Backing from the World's Leading MMA Brand
LAS VEGAS, June 2, 2025 /PRNewswire/ — UFC GYM®, the groundbreaking extension of UFC®, is introducing its newest franchise offering: UFC GYM Jiu-Jitsu. This signature studio model, featuring nearly 2,500 square feet of space dedicated to practicing one of mixed martial arts' most popular practices, is designed to deliver world-class Jiu-Jitsu instruction, integrated MMA-inspired programming and a strong community culture – making it an exciting business opportunity for passionate martial artists and entrepreneurs alike.
Photos available to download here, courtesy of UFC GYM®
Designed with simplicity and scalability in mind, UFC GYM Jiu-Jitsu offers a turnkey franchise model backed by the global power and credibility of the UFC GYM brand. Studios will be led by qualified Jiu-Jitsu practitioners, with instruction provided by experienced coaches, including certified black belts and higher. The model offers an ideal opportunity for black belts who are passionate about teaching but prefer to avoid the complexities of running a business. It's a path to ownership, professional growth and meaningful impact in a rapidly expanding market.
This bold new concept will combine the dynamic discipline with UFC GYM's elite programming, delivering the benefits of MMA in a way that's more accessible to the broader fitness community, while also offering entrepreneurs a proven, high-growth business model backed by one of the most powerful brands in sports. UFC GYM's programming has been developed by top leaders in the discipline, who are certified through a rigorous process, assuring the best guidance in the industry. Members can experience MMA training in an environment that's comfortable for all levels, with programs available for youth and adults, from first-timers to competitive athletes.
For those who desire competition, UFC GYM Jiu-Jitsu will provide access to Alta Global Group's Warrior Training Program, a structured fight-camp-style program that empowers everyday athletes to train like fighters, with the potential to step into the Octagon. Throughout the studios, UFC GYM Jiu-Jitsu will provide unified programming and belt testing developed by elite leaders in the discipline, ensuring consistency in instruction, testing and more. From black belts to professional strikers and mixed martial artists, only UFC GYM provides an all-in-one experience.
'With 2.8 million active practitioners in the U.S. alone, Jiu-Jitsu's popularity continues to surge as more people seek self-defense skills and dynamic fitness training,' said Adam Sedlack, CEO of UFC GYM. 'UFC GYM Jiu-Jitsu delivers an authentic, world-class training experience, backed by UFC's unmatched credibility and brand strength.'
To support franchisees, UFC GYM is partnering with BJJ Link, a premier gym management and engagement platform, to enhance the operational efficiency and community connectivity of its new UFC GYM Jiu-Jitsu studios. BJJ Link provides a full suite of tools for gym operations, student engagement and content monetization, serving more than 50,000 active students and expanding MMA.INC's reach to 18,000 gyms worldwide. The platform seamlessly integrates gym management, payment processing and social connectivity tools, optimizing engagement and revenue generation for gym owners. This collaboration reinforces MMA.INC's mission to unify and modernize the martial arts industry while positioning UFC GYM Jiu-Jitsu as a cutting-edge player in the combat sports ecosystem.
UFC GYM models, including UFC GYM, UFC FIT and Class UFC GYM, now range from 1,500 to more than 85,000 square feet with the addition of the UFC GYM Jiu-Jitsu, and are thoughtfully designed to give members the tools they need to embrace their fighting spirit and achieve their fitness goals. For those inspired by UFC GYM's growth and vision, opportunities to become a part of the brand through ownership are available. With locations already being developed across continents, joining the UFC GYM franchise provides entrepreneurs with the chance to be part of a global leader in the fitness industry. For franchising information, visit www.ufcgymfranchise.com or contact franchiseinfo@ufcgym.com. For more information and a list of locations, please visit www.ufcgym.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Star

2 hours ago

• The Star

A HUB FOR INTEGRATED LIVING

(From left): Cynthia, Daniel and Lucas mark the grand launch of Centrum Iris with a traditional lion dance performance – symbolising prosperity, good fortune and an auspicious beginning for the new development in Cameron Highlands. LBS supports eco-friendly living with Centrum Iris CAMERON HIGHLANDS: LBS Bina Group Bhd has unveiled Centrum Iris, the second precinct of its signature Cameron Centrum township. With a Gross Development Value (GDV) of RM472mil, Centrum Iris is officially the largest mixed commercial development in Cameron Highlands, setting a new benchmark for integrated highland living in Malaysia. Centrum Iris, the second phase of the Cameron Centrum township, marks a significant milestone in LBS' vision to redefine highland living. It builds upon the success of Precinct 1 — Cameron Highlands' largest mixed-use development, completed in 2021 — which features 58 shop-office units ranging from two to five storeys and is now 95% occupied by well-known brands in the food and beverage, banking, healthcare and daily essentials sectors. The thriving commercial ecosystem in Precinct 1 has laid a solid foundation for Centrum Iris, offering a ready catchment of lifestyle convenience and investment appeal. Centrum Iris stands out as the first development in Cameron Highlands to receive the Silver GreenRE Certification reflecting LBS' ongoing commitment to sustainability and environmentally responsible development. Designed to promote green living, the project includes electric vehicle (EV) charging bays, 47 lifestyle-focused facilities and a rooftop cafe and restaurant with panoramic highland views, strategically planned to foster a greener and healthier lifestyle. Strategically located in the heart of Brinchang's bustling commercial district, Centrum Iris offers 705 residential units — ranging from 595 sq ft to 1,370 sq ft and priced from RM476,000 — as well as 26 commercial units ranging from 615 sq ft to 2,944 sq ft, starting from RM676,000. The development seamlessly blends modern architecture with English-inspired aesthetics, creating a distinctive and elevated lifestyle destination in the highlands that caters to both homeowners and investors. Daniel (fourth from right) and the team at the Memorandum of Understanding (MOU) signing ceremony with MyKey International and Dreamscape Hospitality Group, held in conjunction with the grand launch of Centrum Iris in Cameron Highlands. A key highlight of the grand launch event was the signing of a Memorandum of Understanding (MOU) with short-term rental platform operators MyKey International and Dreamscape Hospitality Group. The initiative is set to drive hassle-free returns for LBS purchasers and homeowners. 'Our collaboration with MyKey and Dreamscape enables us to expand Centrum Iris' appeal beyond traditional homeownership, tapping into the short-term rental market in Malaysia's tourism hotspots,' said LBS executive director Datuk Seri Daniel Lim, who officiated the grand opening event. Also present during the event were LBS executive director Datuk Cynthia Lim and deputy chief executive officer Lucas Lim. Centrum Iris has already achieved strong booking rates to date, reflecting growing market confidence in its investment potential. Its central location in Brinchang — a hub for tourism and commerce — positions the development as a prime choice for buyers seeking long-term value and year-round highland appeal. Visitors are welcome to the Centrum Iris Sales Gallery, open daily from 10am to 6pm at C-2-48, Presint 1, Cameron Centrum, Brinchang, Cameron Highlands, Pahang. For added convenience, a Satellite Sales Gallery for Centrum Iris is also available on the ground floor of LBS 2 in Petaling Jaya, Selangor. For more information, contact 1700 81 8778 or visit

New Straits Times

7 hours ago

• New Straits Times

LBS launches Cameron Highlands' largest mixed commercial development

KUALA LUMPUR: LBS Bina Group Bhd has launched Centrum Iris, the largest integrated mixed commercial development in Cameron Highlands, Pahang. With a gross development value (GDV) of RM472 million, the project sets a new benchmark for highland living in Malaysia. Centrum Iris marks the second precinct of LBS' flagship Cameron Centrum township and builds upon the success of Precinct 1, which was completed in 2021. The first phase comprises 58 shop-office units ranging from two to five storeys and is now 95 per cent occupied by major brands in the F&B, banking, healthcare, and retail sectors, laying a strong foundation for Precinct 2's continued growth. The thriving commercial ecosystem in Precinct 1 has laid a solid foundation for Centrum Iris, offering a ready catchment of lifestyle convenience and investment appeal. A key milestone during the launch was the signing of MOUs with MyKey International and Dreamscape Hospitality Group, both of which are leading short-term rental platform operators. The partnership will enable LBS homeowners to tap into Malaysia's booming short-stay tourism market and generate hassle-free rental income. "Our collaboration with MyKey and Dreamscape enables us to expand Centrum Iris' appeal beyond traditional homeownership, tapping into the short-term rental market in Malaysia's tourism hotspots," said executive director of LBS, Datuk Sri Daniel Lim, who officiated the grand launching event. Also present were LBS executive director Datuk Cynthia Lim and deputy chief executive officer Lucas Lim. Strategically located in the heart of Brinchang's bustling commercial district, Centrum Iris offers 705 residential units (ranging from 595 to 1,370 sq ft, starting from RM476,000) and 26 commercial units (ranging from 615 to 2,944 sq ft, starting from RM676,000). According to LBS, the project has already recorded strong bookings, reflecting buyer confidence in its long-term value. Its central location in Brinchang, a hub for tourism and commerce, positions the development as a prime choice for buyers seeking long-term value and year-round highland appeal. Centrum Iris has earned the distinction of being Cameron Highlands' first development to receive the Silver GreenRE Certification, reflecting LBS' strong commitment to sustainable and environmentally conscious development. Its eco-friendly features include electric vehicle (EV) charging bays, 47 lifestyle-oriented facilities, and a rooftop café and restaurant designed to offer sweeping views of the highlands, promoting a greener, healthier way of living. Combining contemporary architecture with English-inspired aesthetics, Centrum Iris offers a unique and elevated lifestyle in the highlands, appealing to both homeowners and investors seeking long-term value and everyday convenience.

Malaysian Reserve

2 days ago

• Malaysian Reserve

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years. 'We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients. This marks another milestone in our partnership with argenx and the expansion of access to Europe is another catalyst supporting our growth,' said Dr. Helen Torley, president and chief executive officer of Halozyme. The EC decision is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. For more information on the study and its findings, please view argenx's press release issued on June 20, 2025. The approval by the EC is valid in all 27 European Union (EU) Member States, as well as Iceland, Norway and Liechtenstein. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indication referred to in this press release. Forward-looking statements may also include statements regarding potential growth catalysts and opportunities driven by the product development and commercialization efforts of Halozyme's ENHANZE® partners. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning unexpected results or delays in the timing of the Halozyme's expected growth catalysts or in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney CharltonTeneo 917-972-8407